Comparison of budesonide Turbuhaler with budesonide aqua in the <font color="red">treatment_1</font> <font color="red">of_1</font> <font color="red">seasonal_2</font> <font color="red">allergic_2</font> <font color="red">rhinitis_2</font> <font color="red">._2</font> Rhinocort Study Group . 
<br>
<br> OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg / day with budesonide aqua 256 microg / day in the <font color="red">treatment_1</font> <font color="red">of_1</font> <font color="red">seasonal_1</font> <font color="red">allergic_1</font> <font color="red">rhinitis_1</font> <font color="red">(_1</font> <font color="red">SAR_1</font> <font color="red">)_1</font> <font color="red">._1</font> Secondarily to ascertain <font color="red">patients_1</font> <font color="red">'_1</font> <font color="red">preferences_1</font> for the two nasal devices and to assess quality of life . 
<br> DESIGN Randomized , multicentre , double - blind , double- dummy , parallel groups study . 
<br> SETTING <font color="red">Private_2</font> <font color="red">practices_2</font> <font color="red">and_2</font> <font color="red">hospital_2</font> <font color="red">clinics_2</font> <font color="red">in_2</font> <font color="red">Ontario_2</font> <font color="red">,_2</font> <font color="red">Quebec_2</font> <font color="red">and_2</font> <font color="red">Manitoba_2</font> <font color="red">._2</font> 
<br> POPULATION <font color="red">Two_5</font> <font color="red">hundred_5</font> <font color="red">and_5</font> <font color="red">eighty_5</font> <font color="red">-_5</font> <font color="red">four_5</font> <font color="red">out_5</font> <font color="red">-_5</font> <font color="red">patients_5</font> <font color="red">with_5</font> <font color="red">SAR_5</font> <font color="red">,_5</font> <font color="red">who_4</font> <font color="red">were_4</font> <font color="red">symptomatic_4</font> <font color="red">during_4</font> <font color="red">the_4</font> <font color="red">ragweed_4</font> <font color="red">season_4</font> <font color="red">,_4</font> <font color="red">volunteered_2</font> <font color="red">for_2</font> <font color="red">enrolment_2</font> <font color="red">(_2</font> <font color="red">243_2</font> <font color="red">randomized_2</font> <font color="red">)_2</font> <font color="red">._2</font> <font color="red">
<br>_1</font> RESULTS Mean daily nasal symptom scores were significantly reduced with treatment . There were no statistically significant changes from baseline for eye symptoms . Most patients ( more than 80% ) achieved substantial control of their symptoms with budesonide . The most common nasal and non - nasal adverse events for both groups were epistaxis and headache . Turbuhaler was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less nasal irritation than the aqua spray . More than twice as many patients preferred Turbuhaler to the aqua spray ( 69% versus 31% ) . Improvement in quality of life from baseline to clinic visits was statistically significant in both groups . 
<br> CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the <font color="red">treatment_1</font> <font color="red">of_1</font> <font color="red">SAR_1</font> <font color="red">._1</font> Patients preferred the budesonide powder formulation delivered via Turbuhaler two to one over the aqua formulation .